25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALZCUR (AlzeCure Pharma) Stock Analysis
Buy, Hold or Sell?

Let's analyze AlzeCure Pharma together

I guess you are interested in AlzeCure Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – AlzeCure Pharma’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – AlzeCure Pharma’s Price Targets

I'm going to help you getting a better view of AlzeCure Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AlzeCure Pharma

I send you an email if I find something interesting about AlzeCure Pharma.

1. Quick Overview

1.1. Quick analysis of AlzeCure Pharma (30 sec.)










1.2. What can you expect buying and holding a share of AlzeCure Pharma? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.18
Expected worth in 1 year
kr0.21
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
kr0.02
Return On Investment
0.8%

For what price can you sell your share?

Current Price per Share
kr3.15
Expected price per share
kr2.3 - kr3.7
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of AlzeCure Pharma (5 min.)




Live pricePrice per Share (EOD)
kr3.15
Intrinsic Value Per Share
kr22.22 - kr26.91
Total Value Per Share
kr22.40 - kr27.10

2.2. Growth of AlzeCure Pharma (5 min.)




Is AlzeCure Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$1.6m$2.9m$122.8k4.0%

How much money is AlzeCure Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$930.2k-$979.6k$49.4k5.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of AlzeCure Pharma (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of AlzeCure Pharma?

Welcome investor! AlzeCure Pharma's management wants to use your money to grow the business. In return you get a share of AlzeCure Pharma.

First you should know what it really means to hold a share of AlzeCure Pharma. And how you can make/lose money.

Speculation

The Price per Share of AlzeCure Pharma is kr3.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AlzeCure Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AlzeCure Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.18. Based on the TTM, the Book Value Change Per Share is kr0.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AlzeCure Pharma.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.01-0.4%-0.01-0.3%-0.01-0.4%-0.01-0.4%-0.02-0.5%-0.02-0.5%
Usd Book Value Change Per Share-0.01-0.4%0.000.0%-0.01-0.3%0.00-0.1%-0.01-0.3%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.4%0.000.0%-0.01-0.3%0.00-0.1%-0.01-0.3%0.000.0%
Usd Price Per Share0.24-0.19-0.35-0.32-0.47-0.41-
Price to Earnings Ratio-4.96--4.54--8.10--6.79--7.25--6.55-
Price-to-Total Gains Ratio-19.83--16.86--32.85--23.38--25.17--25.12-
Price to Book Ratio12.47-6.33-10.64-8.35-8.12-5.83-
Price-to-Total Gains Ratio-19.83--16.86--32.85--23.38--25.17--25.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.329805
Number of shares3032
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (3032 shares)1.89-27.35
Gains per Year (3032 shares)7.58-109.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
108-20-109-119
201560-219-228
3023140-328-337
4030220-438-446
5038300-547-555
6045380-656-664
7053460-766-773
8061540-875-882
9068620-985-991
10076700-1094-1100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%0.030.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%6.022.02.020.0%6.022.02.020.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%6.022.02.020.0%6.022.02.020.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AlzeCure Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1140.006-2019%-0.105-8%-0.043-62%-0.086-25%0.006-1986%
Book Value Per Share--0.1820.332-45%0.318-43%0.392-54%0.631-71%0.962-81%
Current Ratio--2.8404.744-40%4.768-40%4.818-41%6.723-58%14.435-80%
Debt To Asset Ratio--0.3500.230+52%0.239+46%0.215+63%0.183+91%0.136+158%
Debt To Equity Ratio--0.5370.313+72%0.336+60%0.289+86%0.239+125%0.174+209%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--212608104.000185274336.000+15%322503230.460-34%296099592.013-28%441202930.448-52%484796135.415-56%
Eps---0.114-0.101-12%-0.106-7%-0.119+4%-0.155+36%-0.144+25%
Ev To Ebitda Ratio---5.281-5.336+1%-8.893+68%-7.581+44%-8.163+55%-9.187+74%
Free Cash Flow Per Share---0.121-0.102-16%-0.099-18%-0.081-33%-0.155+28%-0.143+18%
Free Cash Flow To Equity Per Share---0.1210.005-2497%-0.098-19%0.037-426%0.010-1358%0.048-350%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.028-3%
Intrinsic Value_10Y_max--26.913----------
Intrinsic Value_10Y_min--22.218----------
Intrinsic Value_1Y_max--0.115----------
Intrinsic Value_1Y_min--0.111----------
Intrinsic Value_3Y_max--2.313----------
Intrinsic Value_3Y_min--2.168----------
Intrinsic Value_5Y_max--6.883----------
Intrinsic Value_5Y_min--6.220----------
Market Cap278129880.000+28%200430104.000159372836.000+26%297481980.460-33%268312925.347-25%393861930.448-49%348998550.693-43%
Net Profit Margin----0%-0%-0%-0%-0.7290%
Operating Margin----0%-0%-0%-0%-0.7290%
Operating Ratio----0%-0%-0%-0%1.264-100%
Pb Ratio17.300+28%12.4676.332+97%10.642+17%8.348+49%8.117+54%5.829+114%
Pe Ratio-6.879-39%-4.957-4.539-8%-8.097+63%-6.792+37%-7.253+46%-6.555+32%
Price Per Share3.150+28%2.2701.805+26%3.369-33%3.039-25%4.461-49%3.953-43%
Price To Free Cash Flow Ratio-6.511-39%-4.692-4.401-6%-8.698+85%-4.6880%-5.846+25%-5.635+20%
Price To Total Gains Ratio-27.516-39%-19.829-16.862-15%-32.846+66%-23.383+18%-25.167+27%-25.120+27%
Quick Ratio--2.8404.550-38%4.768-40%4.754-40%6.643-57%14.241-80%
Return On Assets---0.409-0.259-37%-0.285-30%-0.263-36%-0.245-40%-0.193-53%
Return On Equity---0.629-0.354-44%-0.397-37%-0.351-44%-0.317-50%-0.242-62%
Total Gains Per Share---0.1140.006-2019%-0.105-8%-0.043-62%-0.086-25%0.006-1986%
Usd Book Value--1683261.9003066427.425-45%2943614.325-43%3628038.225-54%5837611.320-71%8893497.200-81%
Usd Book Value Change Per Share---0.0120.001-2019%-0.011-8%-0.005-62%-0.009-25%0.001-1986%
Usd Book Value Per Share--0.0190.035-45%0.033-43%0.041-54%0.066-71%0.101-81%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--22260068.48919398222.979+15%33766088.229-34%31001627.284-28%46193946.818-52%50758155.378-56%
Usd Eps---0.012-0.011-12%-0.011-7%-0.012+4%-0.016+36%-0.015+25%
Usd Free Cash Flow---1118091.300-938714.025-16%-918768.675-18%-744931.775-33%-1431160.005+28%-1322849.600+18%
Usd Free Cash Flow Per Share---0.013-0.011-16%-0.010-18%-0.008-33%-0.016+28%-0.015+18%
Usd Free Cash Flow To Equity Per Share---0.0130.001-2497%-0.010-19%0.004-426%0.001-1358%0.005-350%
Usd Market Cap29120198.436+28%20985031.88916686335.929+26%31146363.354-33%28092363.284-25%41237344.118-49%36540148.258-43%
Usd Price Per Share0.330+28%0.2380.189+26%0.353-33%0.318-25%0.467-49%0.414-43%
Usd Profit---1058307.600-930207.150-12%-979625.550-7%-1096976.800+4%-1433013.195+35%-1326325.640+25%
Usd Revenue----0%-0%-0%-0%10918.064-100%
Usd Total Gains Per Share---0.0120.001-2019%-0.011-8%-0.005-62%-0.009-25%0.001-1986%
 EOD+5 -3MRQTTM+8 -24YOY+3 -293Y+7 -255Y+9 -2310Y+10 -25

3.3 Fundamental Score

Let's check the fundamental score of AlzeCure Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.879
Price to Book Ratio (EOD)Between0-117.300
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.840
Current Ratio (MRQ)Greater than12.840
Debt to Asset Ratio (MRQ)Less than10.350
Debt to Equity Ratio (MRQ)Less than10.537
Return on Equity (MRQ)Greater than0.15-0.629
Return on Assets (MRQ)Greater than0.05-0.409
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of AlzeCure Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.324
Ma 20Greater thanMa 502.846
Ma 50Greater thanMa 1002.809
Ma 100Greater thanMa 2002.563
OpenGreater thanClose2.960
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About AlzeCure Pharma

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.

Fundamental data was last updated by Penke on 2025-06-26 23:23:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ AlzeCure Pharma earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ kr0.00 for each kr1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AlzeCure Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-72.9%+72.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--140.9%+140.9%
YOY--197.6%+197.6%
3Y--248.5%+248.5%
5Y--343.4%+343.4%
10Y-72.9%-496.2%+423.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ AlzeCure Pharma is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • -40.9% Return on Assets means thatΒ AlzeCure Pharma generatedΒ kr-0.41 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AlzeCure Pharma:

  • The MRQ is -40.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-40.9%TTM-25.9%-14.9%
TTM-25.9%YOY-28.5%+2.5%
TTM-25.9%5Y-24.5%-1.4%
5Y-24.5%10Y-19.3%-5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-40.9%-11.6%-29.3%
TTM-25.9%-11.6%-14.3%
YOY-28.5%-11.4%-17.1%
3Y-26.3%-11.8%-14.5%
5Y-24.5%-12.0%-12.5%
10Y-19.3%-13.7%-5.6%
4.3.1.3. Return on Equity

Shows how efficient AlzeCure Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • -62.9% Return on Equity means AlzeCure Pharma generated kr-0.63Β for eachΒ kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AlzeCure Pharma:

  • The MRQ is -62.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -35.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-62.9%TTM-35.4%-27.5%
TTM-35.4%YOY-39.7%+4.3%
TTM-35.4%5Y-31.7%-3.7%
5Y-31.7%10Y-24.2%-7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62.9%-13.5%-49.4%
TTM-35.4%-14.9%-20.5%
YOY-39.7%-14.6%-25.1%
3Y-35.1%-16.8%-18.3%
5Y-31.7%-17.5%-14.2%
10Y-24.2%-19.9%-4.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AlzeCure Pharma.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient AlzeCure Pharma is operatingΒ .

  • Measures how much profit AlzeCure Pharma makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated kr0.00 Β for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AlzeCure Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-72.9%+72.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM--250.5%+250.5%
YOY--209.2%+209.2%
3Y--234.1%+234.1%
5Y--346.1%+346.1%
10Y-72.9%-477.5%+404.6%
4.3.2.2. Operating Ratio

Measures how efficient AlzeCure Pharma is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y1.264-1.264
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM-2.694-2.694
YOY-3.096-3.096
3Y-3.652-3.652
5Y-4.745-4.745
10Y1.2646.614-5.350
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AlzeCure Pharma.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if AlzeCure Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.84Β means the company has kr2.84 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of AlzeCure Pharma:

  • The MRQ is 2.840. The company is able to pay all its short-term debts. +1
  • The TTM is 4.744. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.840TTM4.744-1.905
TTM4.744YOY4.768-0.024
TTM4.7445Y6.723-1.978
5Y6.72310Y14.435-7.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8403.661-0.821
TTM4.7443.846+0.898
YOY4.7684.140+0.628
3Y4.8184.688+0.130
5Y6.7235.746+0.977
10Y14.4356.147+8.288
4.4.3.2. Quick Ratio

Measures if AlzeCure Pharma is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.84Β means the company can pay off kr2.84 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AlzeCure Pharma:

  • The MRQ is 2.840. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.550. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.840TTM4.550-1.711
TTM4.550YOY4.768-0.218
TTM4.5505Y6.643-2.093
5Y6.64310Y14.241-7.598
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8402.848-0.008
TTM4.5503.169+1.381
YOY4.7683.786+0.982
3Y4.7544.311+0.443
5Y6.6435.703+0.940
10Y14.2416.368+7.873
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AlzeCure Pharma.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AlzeCure PharmaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ AlzeCure Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.35Β means that AlzeCure Pharma assets areΒ financed with 35.0% credit (debt) and the remaining percentage (100% - 35.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.350. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.230. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.350TTM0.230+0.119
TTM0.230YOY0.239-0.009
TTM0.2305Y0.183+0.047
5Y0.18310Y0.136+0.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3500.329+0.021
TTM0.2300.349-0.119
YOY0.2390.331-0.092
3Y0.2150.340-0.125
5Y0.1830.349-0.166
10Y0.1360.379-0.243
4.5.4.2. Debt to Equity Ratio

Measures ifΒ AlzeCure Pharma is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 53.7% means that company has kr0.54 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AlzeCure Pharma:

  • The MRQ is 0.537. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.313. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.537TTM0.313+0.225
TTM0.313YOY0.336-0.023
TTM0.3135Y0.239+0.074
5Y0.23910Y0.174+0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5370.379+0.158
TTM0.3130.437-0.124
YOY0.3360.414-0.078
3Y0.2890.450-0.161
5Y0.2390.464-0.225
10Y0.1740.515-0.341
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every kr1 in earnings AlzeCure Pharma generates.

  • Above 15 is considered overpriced butΒ always compareΒ AlzeCure Pharma to theΒ Biotechnology industry mean.
  • A PE ratio of -4.96 means the investor is paying kr-4.96Β for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AlzeCure Pharma:

  • The EOD is -6.879. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.957. Based on the earnings, the company is expensive. -2
  • The TTM is -4.539. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.879MRQ-4.957-1.922
MRQ-4.957TTM-4.539-0.419
TTM-4.539YOY-8.097+3.558
TTM-4.5395Y-7.253+2.714
5Y-7.25310Y-6.555-0.698
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.879-2.356-4.523
MRQ-4.957-2.077-2.880
TTM-4.539-2.574-1.965
YOY-8.097-3.760-4.337
3Y-6.792-3.773-3.019
5Y-7.253-6.193-1.060
10Y-6.555-6.876+0.321
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AlzeCure Pharma:

  • The EOD is -6.511. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.692. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.401. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.511MRQ-4.692-1.819
MRQ-4.692TTM-4.401-0.291
TTM-4.401YOY-8.698+4.297
TTM-4.4015Y-5.846+1.444
5Y-5.84610Y-5.635-0.211
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.511-3.246-3.265
MRQ-4.692-2.705-1.987
TTM-4.401-3.704-0.697
YOY-8.698-4.402-4.296
3Y-4.688-5.070+0.382
5Y-5.846-8.477+2.631
10Y-5.635-9.305+3.670
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ AlzeCure Pharma is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 12.47 means the investor is paying kr12.47Β for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of AlzeCure Pharma:

  • The EOD is 17.300. Based on the equity, the company is expensive. -2
  • The MRQ is 12.467. Based on the equity, the company is expensive. -2
  • The TTM is 6.332. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD17.300MRQ12.467+4.833
MRQ12.467TTM6.332+6.135
TTM6.332YOY10.642-4.310
TTM6.3325Y8.117-1.785
5Y8.11710Y5.829+2.288
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.3002.038+15.262
MRQ12.4671.843+10.624
TTM6.3322.125+4.207
YOY10.6422.442+8.200
3Y8.3482.492+5.856
5Y8.1173.652+4.465
10Y5.8294.311+1.518
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets24,718
Total Liabilities8,641
Total Stockholder Equity16,077
 As reported
Total Liabilities 8,641
Total Stockholder Equity+ 16,077
Total Assets = 24,718

Assets

Total Assets24,718
Total Current Assets24,537
Long-term Assets181
Total Current Assets
Cash And Cash Equivalents 20,819
Net Receivables 3,718
Total Current Assets  (as reported)24,537
Total Current Assets  (calculated)24,537
+/-0
Long-term Assets
Property Plant Equipment 164
Intangible Assets 17
Long-term Assets  (as reported)181
Long-term Assets  (calculated)181
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,641
Long-term Liabilities0
Total Stockholder Equity16,077
Total Current Liabilities
Accounts payable 2,121
Other Current Liabilities 6,520
Total Current Liabilities  (as reported)8,641
Total Current Liabilities  (calculated)8,641
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2,207
Retained Earnings -385,560
Other Stockholders Equity 399,430
Total Stockholder Equity (as reported)16,077
Total Stockholder Equity (calculated)16,077
+/-0
Other
Capital Stock2,207
Cash and Short Term Investments 20,819
Common Stock Shares Outstanding 88,295
Liabilities and Stockholders Equity 24,718
Net Debt -20,819
Net Invested Capital 16,077
Net Working Capital 15,896
Property Plant and Equipment Gross 164



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
> Total Assets 
0
55,971
0
0
66,969
237,782
225,876
215,418
201,596
186,755
176,406
160,057
138,334
117,827
99,065
82,030
68,299
45,647
75,561
55,303
40,486
70,836
57,974
48,119
40,396
32,001
22,688
47,257
42,555
34,435
24,718
24,71834,43542,55547,25722,68832,00140,39648,11957,97470,83640,48655,30375,56145,64768,29982,03099,065117,827138,334160,057176,406186,755201,596215,418225,876237,78266,9690055,9710
   > Total Current Assets 
0
55,705
53,952
0
66,305
237,161
224,581
214,074
200,051
184,963
174,696
158,185
136,397
115,859
97,221
80,293
66,708
44,201
74,259
54,146
39,474
27,505
57,237
47,507
39,893
31,608
22,404
47,042
42,404
34,211
24,537
24,53734,21142,40447,04222,40431,60839,89347,50757,23727,50539,47454,14674,25944,20166,70880,29397,221115,859136,397158,185174,696184,963200,051214,074224,581237,16166,305053,95255,7050
       Cash And Cash Equivalents 
0
53,952
-53,952
0
65,746
234,549
222,054
210,315
196,842
182,499
172,230
153,325
132,976
112,434
94,163
77,915
62,672
41,741
25,683
51,673
37,169
25,577
53,718
45,232
37,461
29,100
19,037
43,916
39,187
31,498
20,819
20,81931,49839,18743,91619,03729,10037,46145,23253,71825,57737,16951,67325,68341,74162,67277,91594,163112,434132,976153,325172,230182,499196,842210,315222,054234,54965,7460-53,95253,9520
       Short-term Investments 
0
0
107,904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000107,90400
       Net Receivables 
0
0
0
0
0
8
16
8
8
16
8
122
80
3,425
3,058
2,378
4,036
2,460
48,576
2,473
2,305
1,928
3,519
2,275
2,432
2,508
3,367
3,126
41
35
3,718
3,71835413,1263,3672,5082,4322,2753,5191,9282,3052,47348,5762,4604,0362,3783,0583,425801228168816800000
       Other Current Assets 
0
1,753
0
0
559
2,604
2,511
3,751
3,201
2,448
2,458
4,738
3,341
3,417
2,978
2,298
4,036
2,460
48,576
2,473
2,305
1,928
3,519
2,275
2,432
2,508
3,367
3,126
3,176
2,678
0
02,6783,1763,1263,3672,5082,4322,2753,5191,9282,3052,47348,5762,4604,0362,2982,9783,4173,3414,7382,4582,4483,2013,7512,5112,604559001,7530
   > Long-term Assets 
0
266
-53,952
0
664
621
1,295
1,344
1,545
1,792
1,710
1,872
1,937
1,968
1,844
1,737
1,591
1,446
1,302
1,157
1,012
43,331
737
612
503
393
284
215
151
224
181
18122415121528439350361273743,3311,0121,1571,3021,4461,5911,7371,8441,9681,9371,8721,7101,7921,5451,3441,2956216640-53,9522660
       Property Plant Equipment 
0
242
0
0
640
597
1,271
1,320
1,521
1,768
1,686
1,848
1,913
1,944
1,820
1,713
1,567
1,422
1,278
1,133
988
852
720
595
486
376
267
198
134
207
164
1642071341982673764865957208529881,1331,2781,4221,5671,7131,8201,9441,9131,8481,6861,7681,5211,3201,271597640002420
       Intangible Assets 
0
17
0
0
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17171717171717171717171717171717171717171717171717171700170
       Other Assets 
0
0
0
0
0
0
0
0
7
0
0
0
0
0
7
7
7
7
7
7
7
42,455
0
0
0
0
0
0
0
0
0
00000000042,455777777700000700000000
> Total Liabilities 
0
4,146
0
0
2,543
4,613
4,674
4,394
3,954
4,748
8,183
10,127
9,859
7,072
11,272
9,930
12,706
12,673
13,890
12,378
8,658
10,354
6,998
6,934
6,866
8,227
8,718
7,883
7,040
8,250
8,641
8,6418,2507,0407,8838,7188,2276,8666,9346,99810,3548,65812,37813,89012,67312,7069,93011,2727,0729,85910,1278,1834,7483,9544,3944,6744,6132,543004,1460
   > Total Current Liabilities 
0
4,146
0
0
2,543
4,613
4,674
4,394
3,954
4,748
8,183
10,127
9,859
7,072
11,272
9,930
12,706
12,673
13,890
12,378
8,658
10,354
6,998
6,934
6,866
8,227
8,718
7,883
7,040
8,250
8,641
8,6418,2507,0407,8838,7188,2276,8666,9346,99810,3548,65812,37813,89012,67312,7069,93011,2727,0729,85910,1278,1834,7483,9544,3944,6744,6132,543004,1460
       Accounts payable 
0
1,332
0
0
1,672
3,646
3,802
3,785
2,707
2,997
6,391
7,636
7,812
3,966
7,232
5,865
7,722
5,971
4,030
4,463
3,117
4,845
1,832
1,972
1,915
2,687
3,254
2,285
1,477
2,685
2,121
2,1212,6851,4772,2853,2542,6871,9151,9721,8324,8453,1174,4634,0305,9717,7225,8657,2323,9667,8127,6366,3912,9972,7073,7853,8023,6461,672001,3320
       Other Current Liabilities 
0
2,814
0
0
871
818
872
609
1,247
1,408
1,792
2,491
2,047
2,202
4,040
4,065
4,984
5,168
9,860
7,915
5,541
3,634
5,166
4,962
4,951
3,622
5,464
5,598
5,563
4,310
6,520
6,5204,3105,5635,5985,4643,6224,9514,9625,1663,6345,5417,9159,8605,1684,9844,0654,0402,2022,0472,4911,7921,4081,247609872818871002,8140
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,971
4,030
4,463
3,117
4,845
1,832
0
0
0
0
0
0
0
0
000000001,8324,8453,1174,4634,0305,97100000000000000000
> Total Stockholder Equity
0
51,825
51,825
0
64,426
233,169
221,202
211,024
197,642
182,007
168,223
149,930
128,475
110,755
87,793
72,100
55,593
32,974
61,671
42,925
31,828
60,482
50,976
41,185
33,530
23,774
13,970
39,374
35,515
26,185
16,077
16,07726,18535,51539,37413,97023,77433,53041,18550,97660,48231,82842,92561,67132,97455,59372,10087,793110,755128,475149,930168,223182,007197,642211,024221,202233,16964,426051,82551,8250
   Common Stock
0
189
0
0
235
944
944
944
944
944
944
944
944
944
944
944
944
944
944
1,268
1,268
1,268
1,552
1,552
1,552
1,552
1,552
2,152
2,207
2,207
2,207
2,2072,2072,2072,1521,5521,5521,5521,5521,5521,2681,2681,268944944944944944944944944944944944944944944235001890
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
51,825
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
303
0
0
284
0
0
0
0
0
0
0
0
0
0000000002840030300000000000000051,82500
   Capital Surplus 
0
0
0
0
0
0
0
0
0
278,728
278,728
278,842
278,842
278,842
278,842
278,842
278,842
278,842
319,882
322,663
322,663
361,981
362,020
362,440
362,440
0
0
0
0
0
0
000000362,440362,440362,020361,981322,663322,663319,882278,842278,842278,842278,842278,842278,842278,842278,728278,728000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
0
62,458
0
0
98,031
279,032
278,651
278,728
278,728
278,728
278,728
278,842
278,842
278,842
278,842
278,842
278,842
278,842
319,882
322,663
322,663
361,981
362,020
362,440
362,440
362,440
362,440
395,897
399,430
399,430
399,430
399,430399,430399,430395,897362,440362,440362,440362,440362,020361,981322,663322,663319,882278,842278,842278,842278,842278,842278,842278,842278,728278,728278,728278,728278,651279,03298,0310062,4580



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-293
Gross Profit0-293
 
Operating Income (+$)
Gross Profit0
Operating Expense-36,144
Operating Income-36,144-36,144
 
Operating Expense (+$)
Research Development24,688
Selling General Administrative11,473
Selling And Marketing Expenses0
Operating Expense36,14436,161
 
Net Interest Income (+$)
Interest Income929
Interest Expense-19
Other Finance Cost-0
Net Interest Income910
 
Pretax Income (+$)
Operating Income-36,144
Net Interest Income910
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,234-37,054
EBIT - interestExpense = -36,010
-35,234
-35,215
Interest Expense19
Earnings Before Interest and Taxes (EBIT)-35,991-35,215
Earnings Before Interest and Taxes (EBITDA)-35,698
 
After tax Income (+$)
Income Before Tax-35,234
Tax Provision-0
Net Income From Continuing Ops-35,234-35,234
Net Income-35,234
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses36,144
Total Other Income/Expenses Net910-910
 

Technical Analysis of AlzeCure Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AlzeCure Pharma. The general trend of AlzeCure Pharma is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AlzeCure Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. AlzeCure Pharma Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AlzeCure Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.5 < 3.7 < 3.7.

The bearish price targets are: 2.4324 > 2.36 > 2.3.

Know someone who trades $ALZCUR? Share this with them.πŸ‘‡

AlzeCure Pharma Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AlzeCure Pharma. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AlzeCure Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AlzeCure Pharma. The current macd is 0.01574708.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the AlzeCure Pharma price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for AlzeCure Pharma. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the AlzeCure Pharma price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
AlzeCure Pharma Daily Moving Average Convergence/Divergence (MACD) ChartAlzeCure Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AlzeCure Pharma. The current adx is 18.96.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy AlzeCure Pharma shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
AlzeCure Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AlzeCure Pharma. The current sar is 2.49013969.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AlzeCure Pharma Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AlzeCure Pharma. The current rsi is 56.32. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
AlzeCure Pharma Daily Relative Strength Index (RSI) ChartAlzeCure Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AlzeCure Pharma. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the AlzeCure Pharma price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
AlzeCure Pharma Daily Stochastic Oscillator ChartAlzeCure Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AlzeCure Pharma. The current cci is 69.20.

AlzeCure Pharma Daily Commodity Channel Index (CCI) ChartAlzeCure Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AlzeCure Pharma. The current cmo is 18.09.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
AlzeCure Pharma Daily Chande Momentum Oscillator (CMO) ChartAlzeCure Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AlzeCure Pharma. The current willr is -32.78381416.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that AlzeCure Pharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AlzeCure Pharma Daily Williams %R ChartAlzeCure Pharma Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of AlzeCure Pharma.

AlzeCure Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AlzeCure Pharma. The current atr is 0.3732497.

AlzeCure Pharma Daily Average True Range (ATR) ChartAlzeCure Pharma Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AlzeCure Pharma. The current obv is 1,677,302.

AlzeCure Pharma Daily On-Balance Volume (OBV) ChartAlzeCure Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AlzeCure Pharma. The current mfi is 44.78.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
AlzeCure Pharma Daily Money Flow Index (MFI) ChartAlzeCure Pharma Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AlzeCure Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

AlzeCure Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AlzeCure Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.324
Ma 20Greater thanMa 502.846
Ma 50Greater thanMa 1002.809
Ma 100Greater thanMa 2002.563
OpenGreater thanClose2.960
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of AlzeCure Pharma with someone you think should read this too:
  • Are you bullish or bearish on AlzeCure Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AlzeCure Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AlzeCure Pharma

I send you an email if I find something interesting about AlzeCure Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about AlzeCure Pharma.

Receive notifications about AlzeCure Pharma in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.